Life Sciences

Michael King, Jr. - Senior Biotechnology Analyst (212-430-1750)

The Latest on the HAE Landscape, Expert Conference Call

Click for Full PDF

Rodman & Renshaw
and MedKnowledge
Invite you to join us for the latest in a series of medical expert conference calls.

Michael G. King, Jr.
Senior Biotechnology Analyst

Will Host

I Can Breathe Easy Now: The Latest on the HAE Landscape

Featuring

Michael Frank, MD
Samuel L. Katz Professor of Pediatrics, Duke Comprehensive Cancer Center
Duke University School of Medicine

Rodman & Renshaw hosts a conference call, with Michael Lacovara and David Horin, Rodman & Renshaw Capital Group’s Chief Executive Officer and Chief Financial Officer, respectively, discussing the Company's quarterly results.

About Rodman & Renshaw Capital Group, Inc.

Rodman & Renshaw Capital Group, Inc. is a holding company with a number of direct and indirect subsidiaries, including Rodman & Renshaw, LLC, Rodman Principal Investments, LLC and Miller Mathis & Co., LLC.

Reports Record Second Quarter Revenue, up 95% Sequentially

Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM - News) today announced its results for the second quarter ended June 30, 2008.

Rodman & Renshaw and MedKnowledge present the latest in a series of medical expert conference calls.

The call was hosted by senior biotechnology analysts Elemer Piros, Ph.D. (pictured right) and Raghuram Selvaraju, Ph.D.

Featuring: Lon Schneider, M.D.

Rodman & Renshaw Capital Group, Inc (NASDAQ: RODM - News), today announced that it will release financial results for the quarter ended June 30, 2008 at 8:00 AM Eastern on Tuesday, August 12, 2008. The Company will hold a conference call to discuss the results at 10:00 AM Eastern on Tuesday, August 12, 2008, which will be hosted by Michael Lacovara and David Horin, Rodman & Renshaw Capital Group’s Chief Executive Officer and Chief Financial Officer, respectively.

Rodman & Renshaw Capital Group, Inc (NASDAQ: RODM - News), today announced that its Rodman & Renshaw, LLC subsidiary has maintained its leading position in PIPE transaction deal volume for the first half of 2008, garnering the top spot in PlacementTracker’s First Half 2008 PIPE Market League Tables, published by Sagient Research Systems. During the first half of 2008 Rodman completed 25 transactions raising a total of $404 million. Rodman was the number one ranked PIPE advisor by deal volume for all of 2007 as well.

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM - News) today announced that it has hired three new research analysts to cover the oil and gas and metals and mining sectors.

Jeff Hayden, who will join Rodman as a Managing Director and Senior Oil and Gas Analyst on Monday, July 21 has 10 years of experience in energy research and finance and was formerly associated with Pritchard Capital Partners. Chad Mabry, also formerly associated with Pritchard Capital, will join the firm as an Associate Oil and Gas Analyst on July 21. Both analysts will be resident in Rodman’s Houston office.

Wilfredo Ortiz, who will join Rodman as a Managing Director and Senior Metals and Mining Analyst on August 18, has 12 years of industry experience. Mr. Ortiz, who was most recently a Managing Director at Bear Stearns & Co., was previously an analyst at JPMorgan Chase. Mr. Ortiz will be resident in Rodman’s New York office.

Rodman & Renshaw and Close Concerns present the latest in a series of medical expert conference calls

The call features David G. Orloff, MD, Medical Director / Medical & Regulatory Affairs of Medpace, Inc.

Rodman & Renshaw and MedKnowledge present the latest in a series of medical expert conference calls.

Senior Biotechnology Analyst Michael G. King, Jr. hosts the call, featuring Arthur F. Kavanaugh, MD, Professor of Clinical Medicine, Director, Center for Innovative Therapy, Division of Rheumatology, Allergy and Immunology, University of California, San Diego.

Dr. Arthur Kavanaugh is a Professor of Clinical Medicine and Director at the Center for Innovative Therapy, Division of Rheumatology, Allergy and Immunology at the University of California at San Diego. Dr. Kavanaugh’s research interest include innovative strategies for the treatment of patients with rheumatoid arthritis and other rheumatic diseases, prognostic and predictive factors for outcomes in rheumatic diseases and research programs on approaches to various immunologic diseases, particularly novel biologic therapies. Dr. Kavanaugh has authored dozens of publications in manuscripts, chapters and books.

Rodman & Renshaw and MedKnowledge present the latest in a series of medical expert conference calls.

Senior Biotechnology Analysts Michael G. King, Jr. & Vernon Bernardino host the call, featuring Silvio E. Inzucchi, MD, Professor of Medicine, Section of Endocrinology, Yale University (Clinical Director, Yale-New Haven Hospital, Director of Yale Diabetes Center)

Vernon T. Bernardino, Senior BioTech Analyst at Rodman & Renshaw, hosted a call with Sherwyn L. Schwartz (pictured right), MD, CEO and Chief Medical Officer, Diabetes and Glandular Disease Research Inc., and Giovanni Solinas, PhD, Director of the Laboratory of Medical Stress Biology, Dept. of Medicine, University of Fribourg, Switzerland

Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM - News), today announced that Ramnarain “Joe” Jaigobind has joined Rodman as Head of Global Capital Markets and President of Middle East, India and Japan markets. Mr. Jaigobind joins Rodman from Maxim Group with a team of eight professionals, significantly strengthening Rodman’s Global Capital Markets practice.

Mr. Jaigobind has significant experience in the public equity markets. He will spearhead Rodman’s initiatives to expand its origination and distribution of initial and secondary public offerings and its participation in syndicated public offerings led by other firms. These enhanced capabilities will complement Rodman’s #1 ranked position in PIPE offerings1, by both broadening the range of capital markets options available to its corporate clients and expanding its investor client base.

Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM - News), today announced that it has completed the acquisition of COSCO Capital Management LLC and its related companies, a leading private investment bank focused on the oil and gas sectors in the United States and Canada. Rodman previously announced that it had entered into definitive agreements to acquire the COSCO companies on May 12, 2008.

Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM - News), today announced that it has added two Senior Managing Directors, Steven Wasserman and Allan Schwartz, to its new Global Capital Markets Group.

Messrs. Wasserman and Schwartz have wide-ranging and significant experience in the origination of both public offerings and strategic advisory engagements in the shipping, technology, homeland security and restaurants sectors, and substantial experience with Special Purpose Acquisition Companies (SPACS) financing transactions.

The addition of Messrs. Wasserman and Schwartz, and the creation of the Global Capital Markets Group demonstrate Rodman’s commitment to broadening and deepening its capital markets capabilities, and building on the firm’s longstanding #1 ranking in PIPE offerings.1

Rodman & Renshaw Capital Group, Inc (NASDAQ: RODM - News), today announced that Michael Lacovara, Chief Executive Officer, will be presenting at Sandler O’Neill & Partners’ 2008 Global Exchange and Electronic Trading Conference taking place at the Grand Hyatt New York, on Friday, June 6 at 8.30 a.m. ET.

A live webcast and audio conference of the presentation will be available. The webcast may be accessed through the Rodman & Renshaw Capital Group, Inc. website at: http://www.thomson-webcast.net/us/dispatching/SOP_20080605 and the audio conference will be available by dialing: 800-659-1966 and stating the passcode: “Session 2.”

Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM - News), today announced that Senior Biotechnology Analyst Dr. Elemer Piros has been named one of the “World’s Top Analysts” by the Financial Times (“FT”). The FT, in a May 16, 2008 report and survey published in conjunction with StarMine, examined the 2007 performance of research analysts from Asia, Europe and the US, and honored as the “World’s Best” the top three stock pickers and earnings estimators in each industry.

Dr. Piros, who specializes in biotechnology, was recognized as one of the top three analysts in the entire Pharmaceutical category.

Michael Lacovara, Chief Executive Officer, commented: “The FT and StarMine have confirmed what Rodman and its clients have long known – Elemer Piros is a leading light in biotech research, a committed and insightful analyst, and a cornerstone of our distinguished life science research team.”

Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM - News) today announced its results for the first quarter ended March 31, 2008.

Net revenue for the quarter was $15.2 million, representing an increase of 5% from $14.5 million in the fourth quarter of 2007. The Company reported net income of $1.1 million, or $0.03 per share, for the quarter, compared to a net loss of $1.6 million, or ($0.05) per share, for the fourth quarter of 2007. The Company reported net income on a non-U.S. GAAP basis of $1.7 million, or $0.05, per share, compared to a net loss of $1.1 million or ($0.03) per share for the fourth quarter of 2007.1

“During this quarter we have continued to expand our franchise and add talented professionals to our team and businesses to our platform,” commented Michael Lacovara, Chief Executive Officer of Rodman & Renshaw. “We continued to execute on our strategic plan for the year, despite the very challenging market environment.”

Transaction Will Create the Rodman Energy Group

Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM - News), today announced that it has entered into a definitive agreement to acquire the operating assets of COSCO Capital Management LLC and its related companies, a leading private investment bank focused on the oil and gas sectors, principally in the United States and Canada. Concurrent with the closing of the transaction, Rodman will create the Rodman Energy Group, which will continue and expand COSCO’s existing investment advisory and finance practice for companies and funds active in the energy sector. The group will be led by Cameron O. Smith, COSCO’s Founder and Senior Managing Director and will include COSCO’s other principals, who are seasoned oil and gas sector investment banking professionals. The transaction is expected to close during the second fiscal quarter.

Forms JV with Aceras Partners, LLC to Make Principal Investments in Biotechnology

Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM - News) today announced the formation of Aceras BioMedical LLC (“Aceras BioMedical”), a joint venture through which Rodman, in partnership with Aceras Partners, LLC (“Aceras Partners”), an established team of biotech research and investment specialists, will make principal investments in early-stage biotechnology and life sciences companies. The founders of Aceras Partners formed the firm following their tenures most recently at Paramount BioSciences, LLC. Collectively, the Aceras Partners team has completed numerous product licenses and acquisitions, leading to the formation of many notable private and public biotechnology companies, which produced significant returns to early-stage investors.